Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia.
It has been discussed if computed tomography (CT) scan is necessary to perform or not, to provide prognostic information in patients with chronic lymphocytic leukemia. In the current National Institute Chronic lymphocytic leukemia Working Group (NCI-WG) guidelines, CT scan is not recommended outside clinical trials but states that further trials are warranted. Computed tomography scan of lymphadenopathy and/or splenomegaly was detected in totally 74 patients, leading to a modified Rai stage in 9 (12%) patients (from stage I to II). Using CT, 19 patients fulfilled the GELF high tumor burden criteria and/or one bulky node > or =7 cm. CT showed splenomegaly in totally 54 (73%) patients, of which 22 (41%) cases had not had been detected during clinical examination. According to the NCI response criteria for chronic lymphocytic leukemia (CLL), 15 (22%) patients showed a CR and 43 (62%) a PR, while when including CT findings, 12 (17%) fulfilled criteria for CR and 41 (59%) for PR. Patients with a high lymphadenopathy tumor burden according to the GELF criteria at the time of initiation of first-line therapy had a shorter time from response to next therapy or death, 12 months compared with 35 months for patients with less advanced lymphadenopathy (P = 0.002). There was also a trend for a shorter overall survival in the high tumor burden group, 58 months compared to 75 months (P = 0.098). Massive splenomegaly was related to a shorter therapy-free as well as overall survival. In our opinion, clinical examination is not sufficient for evaluation of abdominal lymphnodes and spleen in patients with therapy requiring CLL.
Norin
Stefan
S
Department of Hematology, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.
Kimby
Eva
E
Lundin
Jeanette
J
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging / Q000379:methods*; D010173:Palpation; D011379:Prognosis; D012189:Retrospective Studies; D013154:Spleen / Q000473:pathology / Q000528:radiation effects; D013163:Splenomegaly / Q000000981:diagnostic imaging / Q000209:etiology / Q000473:pathology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D047368:Tumor Burden
D000970:Antineoplastic Agents
Ann Oncol. 1996 Apr;7(4):373-9
8805929
J Clin Oncol. 2005 May 1;23(13):2971-9
15738539
Leukemia. 2007 May;21(5):956-64
17361231
Cancer. 1981 Jul 1;48(1):198-206
7237385
J Clin Oncol. 2007 Dec 10;25(35):5624-9
17984187
Cancer. 2005 Sep 1;104(5):1066-74
16047335
N Engl J Med. 1993 Nov 25;329(22):1608-14
8232429
Br J Haematol. 2002 Mar;116(3):538-48
11849209
Blood. 2002 Aug 1;100(3):768-73
12130484
Hematol Oncol Clin North Am. 1990 Apr;4(2):447-56
2182601
J Clin Oncol. 1996 Jul;14(7):2160-6
8683250
J Clin Oncol. 1997 Apr;15(4):1567-74
9193354
J Clin Oncol. 1999 Apr;17(4):1244
10561185
Blood. 1975 Aug;46(2):219-34
1139039
J Clin Oncol. 2007 Apr 20;25(12):1576-80
17353549
Blood. 2008 Jun 15;111(12):5446-56
18216293
Blood. 1996 Jun 15;87(12):4990-7
8652811
Blood. 2006 Feb 1;107(3):885-91
16219797
Best Pract Res Clin Haematol. 2002 Sep;15(3):429-47
12468398